Zimmer Biomet : Investor Deck (zimmer biomet announces definitive agreement to acquire monogram technologies inc ir deck)

Published: 2025-07-14 08:04:08 ET ZBH

Published on 07/14/2025 at 08:04

ZIMMER BIOMET

July 14, 2025

Zimmer Biomet has entered into a definitive agreement to acquire all of the outstanding shares of Monogram Technologies Inc. (NASD:MGRM), a developer of semi- and fully-autonomous1, AI-driven orthopedic robotic systems. The transaction values Monogram at approximately $168 million2, is expected to be neutral to EPS3 in 2025 - 2027 and accretive thereafter, and expected to contribute to revenue growth beginning in 2027.

Summary

Monogram has received FDA clearance for mBôs, a semi-autonomous, AI-navigated total knee arthroplasty (TKA) robotic solution, and is currently developing a fully autonomous version. Monogram's objective is to improve the accuracy, safety and speed of TKAs while expanding mBôs' label to include additional applications.

Upon closing, the transaction will leap Zimmer Biomet forward by offering orthopedic surgeons the most comprehensive suite of customer-centric technology solutions, ranging from simplified navigation, such as OrthoGrid, to non-CT based robotics with ROSA, and fully autonomous robotics1 with mBôs. This acquisition underscores Zimmer Biomet's commitment to enabling today while defining the future of orthopedic surgery.

Monogram's fully-autonomous TKA robot is currently in development, we anticipate late 2027/early 2028 launch; the semi-autonomous robot is regulatory approved with a Monogram implant

3

Represents enterprise value and excludes an up to $12.37 per share Contingent Value Right (CVR)

Based on ZBH internal model expectations, on an adjusted, non-GAAP basis and assuming a 2H2025 deal close

mBôs Overview

KEY FEATURES

Robotic joint arm with 7 degrees of freedom

Robotic-controlled saw, with capabilities for burring/reaming 1

CT-based planning and navigation

AI/ML driven personalized case planning

Markerless tracking1

Augmented reality integration1

Capable of fully remote surgery1

No external fixation enabled by dynamic compensation

2 versions targeting broad surgeon base:

Launch with Persona knee expected early-2027

Launch with Persona knee expected late-2027/early-2028

Initial approval for TKA; pursuing additional indications

Has not yet received regulatory approval

FDA approved to be used with Monogram implants

Currently in development, we anticipate late 2027/early 2028 launch 4

ZBH's Full Suite1 of Robotic and Navigational Solutions

Committed to Broadest Offering in Industry to Address Customer Needs

ROSA ROBOTIC SYSTEM

Image-less or CT-enabled pre-planning2, manual cuts

Robotics Offerings

mBôs

Fully and Semi-Autonomous Versions3 with CT-based pre- and intraoperative-planning

Navigation

TMINI4

CT-enabled, handheld, smaller footprint

Now and in the

ORTHOGRID HIPINSIGHT4

Future

AI-based, direct anterior hip navigation system without pins, CT or MRI

CT-based 3D planning for direct anterior and posterior workflows

egulatory approvals and approval of the

Inclusion of mBôs as within ZBH's Suite of Solutions is subject to transaction closing, which is subject to receipt of required r Monogram common stockholders

CT-enabled ROSA has not yet received regulatory approval

5

mBôs fully-Autonomous robot is currently in development; we anticipate late 2027/early 2028 launch

ZBH has partnership agreements with ThinkSurgical and HipInsight

Disclaimer

Zimmer Biomet Holdings Inc. published this content on July 14, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on July 14, 2025 at 12:03 UTC.